Evaluation of Specific PET Radioligand Binding To Translocator Protein

Trial Profile

Evaluation of Specific PET Radioligand Binding To Translocator Protein

Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2017

At a glance

  • Drugs RP 52028 (Primary) ; XBD 173
  • Indications Neurological disorders
  • Focus Diagnostic use
  • Most Recent Events

    • 17 Jun 2016 Status changed from suspended to completed.
    • 07 May 2016 Status changed from recruiting to suspended.
    • 20 Jan 2016 Change in treatment table: Dose of blocking agent Emapunil decreased from 45mg to 15mg as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top